Recurrent Hypersomnia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: RCR002 MIFTS: 32	Recurrent Hypersomnia Categories: Mental diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Collapse all tables

Sources

Aliases & Classifications for Recurrent Hypersomnia

MalaCards integrated aliases for Recurrent Hypersomnia:

Name: Recurrent Hypersomnia ¹¹ ¹⁴

Disorders of Excessive Somnolence ⁴³

Primary Recurrent Hypersomnia ¹¹

Hypersomnia, Recurrent ⁷¹

Hypersomnia Recurrent ⁵³

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the nervous system

Episodic and paroxysmal disorders

Sleep disorders

Disorders of excessive somnolence [hypersomnias]

External Ids:

Disease Ontology ¹¹ DOID:8619

ICD9CM ³⁴ 327.13

MeSH ⁴³ D006970

SNOMED-CT ⁶⁸ 426451004

ICD10 ³¹ G47.1

UMLS ⁷¹ C0751226

Sources

Summaries for Recurrent Hypersomnia

Disease Ontology: ¹¹ A sleep disorder that involves recurring bouts of excessive amounts of sleepiness.

MalaCards based summary: Recurrent Hypersomnia, also known as disorders of excessive somnolence, is related to hypersomnia and idiopathic hypersomnia. An important gene associated with Recurrent Hypersomnia is HCRT (Hypocretin Neuropeptide Precursor), and among its related pathways/superpathways is Orexin and neuropeptides FF and QRFP bind to their respective receptors. The drugs Fluticasone and Selegiline have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and heart, and related phenotypes are nervous system and behavior/neurological

Sources

Related Diseases for Recurrent Hypersomnia

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Recurrent Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 61, show less)

#	Related Disease	Score	Top Affiliating Genes
1	hypersomnia	31.2	HLA-DQB1 HCRT
2	idiopathic hypersomnia	31.2	HLA-DQB1 HCRT
3	narcolepsy 1	30.2	P2RY11 HLA-DQB1 HCRT
4	rem sleep behavior disorder	29.9	IGLON5 HCRT
5	narcolepsy	29.3	P2RY11 HLA-DQB1 HCRTR2 HCRT
6	migraine with or without aura 1	29.2	HRH3 HCRTR2 HCRT
7	kleine-levin hibernation syndrome	29.1	TRANK1 TOR1B PNMA2 P2RY11 LMOD3 LGI1
8	sleep disorder	29.0	IGLON5 HRH3 HLA-DQB1 HCRTR2 HCRT
9	cranioectodermal dysplasia	10.4
10	narcolepsy 2	10.2	HLA-DQB1 HCRT
11	central sleep apnea	10.1	IGLON5 HCRT
12	autoimmune disease	10.1
13	oculodentodigital dysplasia	10.1
14	tatton-brown-rahman syndrome	10.1
15	guillain-barre syndrome	10.1	HLA-DQB1 HCRT
16	apnea, obstructive sleep	10.0	IGLON5 HCRT
17	sleep apnea	10.0
18	encephalopathy	10.0
19	postinfectious encephalitis	10.0	PNMA2 LGI1
20	akinetic mutism	10.0	PNMA2 LGI1
21	neurosarcoidosis	10.0	PNMA2 LGI1
22	gummatous syphilis	10.0	PNMA2 LGI1
23	chorea gravidarum	10.0	LGI1 IGLON5
24	meningovascular neurosyphilis	10.0	PNMA2 LGI1
25	miller fisher syndrome	10.0	PNMA2 LGI1
26	neuromuscular junction disease	10.0	PNMA2 LGI1
27	headache	10.0	HLA-DQB1 HCRTR2
28	autoimmune neuropathy	10.0	LGI1 IGLON5
29	advanced sleep phase syndrome	10.0	HCRTR2 HCRT
30	periodic limb movement disorder	10.0	HLA-DQB1 HCRTR2 HCRT
31	viral encephalitis	10.0	PNMA2 LGI1
32	demyelinating polyneuropathy	9.9	LGI1 IGLON5
33	anterograde amnesia	9.9	PNMA2 LGI1 HCRT
34	pervasive developmental disorder	9.9
35	autism spectrum disorder	9.9
36	migraine with aura	9.9
37	brain cancer	9.9
38	hepatic encephalopathy	9.9
39	endogenous depression	9.9
40	status epilepticus	9.9
41	post-traumatic stress disorder	9.9
42	bipolar disorder	9.9
43	mood disorder	9.9
44	migraine with brainstem aura	9.9
45	traumatic brain injury	9.9
46	rare pervasive developmental disorder	9.9
47	neuromyelitis optica	9.9	HLA-DQB1 HCRT
48	thymus gland disease	9.8	PNMA2 LGI1
49	autoimmune epilepsy	9.8	PNMA2 LGI1 IGLON5
50	la crosse encephalitis	9.8	PNMA2 LGI1 IGLON5
51	lingual-facial-buccal dyskinesia	9.8	PNMA2 LGI1 IGLON5
52	whipple disease	9.8	PNMA2 LGI1 IGLON5
53	mutism	9.8	PNMA2 LGI1 IGLON5
54	stiff-person syndrome	9.8	PNMA2 LGI1 IGLON5
55	limbic encephalitis	9.8	PNMA2 LGI1 IGLON5
56	autoimmune disease of peripheral nervous system	9.8	PNMA2 LGI1 IGLON5
57	choreatic disease	9.8	PNMA2 LGI1 IGLON5
58	thymus cancer	9.8	PNMA2 LGI1
59	hyperekplexia	9.8	PNMA2 LGI1 IGLON5
60	acute disseminated encephalomyelitis	9.7	PNMA2 LGI1 IGLON5 HCRT
61	von economo's disease	9.6	LGI1 IGLON5 HCRTR2 HCRT

Graphical network of the top 20 diseases related to Recurrent Hypersomnia:

Sources

Symptoms & Phenotypes for Recurrent Hypersomnia

MGI Mouse Phenotypes related to Recurrent Hypersomnia:

⁴⁵ (showing 2, show less)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	9.5	HCRT HCRTR2 HLA-DQB1 HRH3 LGI1 LMOD3
2	behavior/neurological	MP:0005386	9.23	HCRT HCRTR2 HLA-DQB1 HRH3 LGI1 LMOD3

Sources

Drugs & Therapeutics for Recurrent Hypersomnia

Drugs for Recurrent Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 72, show less)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Fluticasone

Approved, Experimental

Phase 4

90566-53-3

4659387 5311101

Selegiline

Approved, Investigational, Vet_approved

Phase 4

14611-51-9, 14611-52-0

5195 26757

Varenicline

Approved, Investigational

Phase 4

249296-44-4

5310966

Hormones

Phase 4

Psychotropic Drugs

Phase 4

Antidepressive Agents

Phase 4

Sympathomimetics

Phase 4

Fluticasone-Salmeterol Drug Combination

Phase 4

Bronchodilator Agents

Phase 4

Adrenergic beta-Agonists

Phase 4

Anti-Asthmatic Agents

Phase 4

Adrenergic Agonists

Phase 4

Anti-Allergic Agents

Phase 4

Xhance

Phase 4

Hormone Antagonists

Phase 4

glucocorticoids

Phase 4

Respiratory System Agents

Phase 4

Anti-Inflammatory Agents

Phase 4

Dermatologic Agents

Phase 4

Salmeterol Xinafoate

Phase 4

94749-08-3

Protective Agents

Phase 4

Neuroprotective Agents

Phase 4

Antiparkinson Agents

Phase 4

Monoamine Oxidase Inhibitors

Phase 4

Neurotransmitter Agents

Phase 4

Nicotinic Agonists

Phase 4

Cholinergic Agents

Phase 4

Modafinil

Approved, Investigational

Phase 2, Phase 3

68693-11-8

4236

Methylphenidate

Approved, Investigational

Phase 2, Phase 3

113-45-1

4158

Dopamine

Approved

Phase 2, Phase 3

62-31-7, 51-61-6

681

Sodium citrate

Approved, Investigational

Phase 2, Phase 3

68-04-2

23431961

Sodium oxybate

Approved

Phase 3

502-85-2

23663870

Esreboxetine

Approved, Experimental, Investigational

Phase 3

98769-81-4, 71620-89-8, 98819-76-2

65856

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3

77-92-9

311

Central Nervous System Stimulants

Phase 2, Phase 3

Phosphodiesterase Inhibitors

Phase 2, Phase 3

Dopamine Uptake Inhibitors

Phase 2, Phase 3

Dopamine Agents

Phase 2, Phase 3

Anesthetics, Intravenous

Phase 2, Phase 3

Anesthetics, General

Phase 2, Phase 3

Anesthetics

Phase 2, Phase 3

Citrate

Phase 2, Phase 3

Pharmaceutical Solutions

Phase 3

Adrenergic Agents

Phase 3

Flumazenil

Approved

Phase 1, Phase 2

78755-81-4

3373

Mirtazapine

Approved

Phase 2

85650-52-8, 61337-67-5

4205

Mazindol

Approved, Investigational

Phase 2

22232-71-9

4020

Flecainide

Approved, Withdrawn

Phase 2

54143-55-4

3356

Dextroamphetamine

Approved, Illicit, Investigational

Phase 2

51-64-9, 300-62-9

5826 3007

Clarithromycin

Approved

Phase 2

81103-11-9

84029

Pentetrazol

Experimental, Withdrawn

Phase 2

54-95-5

Convulsants

Phase 2

Adrenergic Antagonists

Phase 2

Adrenergic alpha-Antagonists

Phase 2

Anti-Anxiety Agents

Phase 2

Serotonin 5-HT3 Receptor Antagonists

Phase 2

Histamine H1 Antagonists

Phase 2

Histamine Antagonists

Phase 2

Antidotes

Phase 1, Phase 2

GABA Modulators

Phase 1, Phase 2

Adderall

Phase 2

Anti-Bacterial Agents

Phase 2

Anti-Infective Agents

Phase 2

Cytochrome P-450 Enzyme Inhibitors

Phase 2

Cytochrome P-450 CYP3A Inhibitors

Phase 2

Antibiotics, Antitubercular

Phase 2

Serotonin

Investigational, Nutraceutical

Phase 2

50-67-9

5202

Caffeine

Approved

58-08-2

2519

Benzocaine

Approved, Investigational

1994-09-7, 94-09-7

2337

Tannic acid

Approved

1401-55-4

16129878 16129778

Melatonin

Approved, Nutraceutical, Vet_approved

73-31-4

896

Antioxidants

Interventional clinical trials:

(showing 127, show less)

#	Name	Status	NCT ID	Phase	Drugs
1	The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study	Unknown status	NCT02385656	Phase 4	Modafinil
2	Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea	Completed	NCT00711516	Phase 4	Armodafinil;Placebo
3	Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function	Completed	NCT04789174	Phase 4	Solriamfetol;Placebo
4	TITLE: Double-blinded, Double-dummy, Study Comparing Fluticasone-salmeterol to Placebo in Patients With COPD and Associated Poor Sleep or Daytime Somnolence.	Completed	NCT00731770	Phase 4	Advair 250;Placebo- matched;Placebo;Advair 250 - matched
5	Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness	Completed	NCT00127348	Phase 4
6	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder	Completed	NCT01080807	Phase 4	Armodafinil;Matching Placebo
7	A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease	Completed	NCT04870372	Phase 4	Selegiline
8	A Phase 4, Open-Label, Single-Dose Study to Evaluate Sunosi® (Solriamfetol) Pharmacokinetics in Breast Milk and Plasma of Healthy Postpartum Women Following Oral Administration of Sunosi®	Completed	NCT05008341	Phase 4	Solriamfetol 150 mg Oral Tablet
9	Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder	Recruiting	NCT04788953	Phase 4	Solriamfetol Oral Tablet;Placebo
10	Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study	Terminated	NCT02473562	Phase 4	Varenicline;Placebo (for varenicline)
11	The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study	Completed	NCT03682185	Phase 3
12	A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy	Completed	NCT02720744	Phase 3	FT218;Placebo
13	A 3-Day, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Armodafinil Treatment (50 and 150 mg/Day) in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder	Completed	NCT00758498	Phase 3	armodafinil;placebo
14	Caffeine for Excessive Daytime Somnolence in Parkinson's Disease	Completed	NCT00459420	Phase 2, Phase 3	Caffeine 100-200 mg BID;placebo
15	Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness	Completed	NCT02739568	Phase 3	Pitolisant (BF2.649);Placebo
16	A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase	Completed	NCT01066442	Phase 3	BF2.649 (Pitolisant)
17	Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy	Completed	NCT00066170	Phase 3	Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo)
18	Randomized, Double-blind, Placebo and Comparator-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy	Completed	NCT01638403	Phase 3	BF2.649;Vigil;palcebo
19	BF2.649 in Patients With Obstructive Sleep Apnea Syndrome (OSA) and Treated by Nasal Continuous Positive Airway Pressure (nCPAP), But Still Complaining of Excessive Daytime Sleepiness (EDS)	Completed	NCT01071876	Phase 3	BF2.649;Placebo
20	Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy	Completed	NCT01067235	Phase 3	BF2.649;BF2.649 add on Modafinil
21	A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase	Completed	NCT01036139	Phase 3	BF2.649 (pitolisant)
22	Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy	Completed	NCT01067222	Phase 3	BF2.649;Modafinil;Placebo
23	A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)	Completed	NCT00228553	Phase 3	Armodafinil 100 to 250 mg/day
24	A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome	Completed	NCT00228566	Phase 3	Armodafinil
25	A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension	Completed	NCT03533114	Phase 3	JZP-258;Placebo Oral Solution
26	A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder	Completed	NCT00080288	Phase 3	Armodafinil 150 mg/day;Placebo
27	Efficacy and Safety of BF2.649 in Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea (OSA) Refusing the Nasal Continuous Positive Airway Pressure (nCPAP) Therapy	Completed	NCT01072968	Phase 3	BF2.649;Placebo
28	An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up)	Completed	NCT01399606	Phase 3	BF2.649
29	A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia	Completed	NCT02151253	Phase 2, Phase 3	Armodafinil;Placebo
30	A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy.	Completed	NCT01800045	Phase 3	Pitolisant;Placebo
31	Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1	Completed	NCT01421992	Phase 2, Phase 3	Methylphenidate;Placebo
32	A Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Assess the Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy	Recruiting	NCT05059223	Phase 3	AXS-12 (reboxetine);Placebo
33	A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia	Recruiting	NCT05156047	Phase 3	Pitolisant Oral Tablet;Placebo oral tablet
34	A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia	Recruiting	NCT03597555	Phase 2, Phase 3	Sodium Oxybate Oral Solution 500 MG/ML;Placebos
35	A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea	Recruiting	NCT05223166	Phase 3	Pitolisant;Placebo oral tablet
36	Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR	Active, not recruiting	NCT04451668	Phase 3	FT218
37	A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy	Enrolling by invitation	NCT05113745	Phase 3	AXS-12 (reboxetine);Placebo
38	An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010	Enrolling by invitation	NCT05458128	Phase 3	pitolisant
39	Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness	Withdrawn	NCT02978651	Phase 3	Pitolisant (BF2.649);Placebo Oral Tablet
40	A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia	Unknown status	NCT03542851	Phase 2	Pentetrazol (PTZ);Placebo oral capsule
41	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Hypnotic Efficacy of EVT 201 in Elderly Patient With Daytime Sleepiness	Completed	NCT00401284	Phase 2	EVT 201
42	A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease	Completed	NCT00641186	Phase 2	sodium oxybate
43	A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy	Completed	NCT01681121	Phase 2	ADX-N05;Placebo
44	Randomized, Dose-finding Study of BF 2.649 5, 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD)	Completed	NCT00642928	Phase 2	Placebo;BF 2.649 5 mg;BF 2.649 10 mg;BF 2.649 20 mg;BF 2.649 40 mg
45	A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness	Completed	NCT03037203	Phase 2	JZP-110
46	Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder	Completed	NCT00385437	Phase 2	Mirtazapine Treatment
47	A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy	Completed	NCT04923594	Phase 2	mazindol extended release;Placebo
48	Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).	Completed	NCT03194217	Phase 2	BEN-2001;Placebo
49	Clarithromycin for the Treatment of Hypersomnia	Completed	NCT01146600	Phase 2	Clarithromycin followed by placebo;Placebo then Clarithromycin
50	Minimum Effective Dose-Finding Study of BF2.649, in Patients With Moderate to Severe OSA, Experiencing EDS Despite Regular Use of nCPAP, and Patients Having Refused This Therapy - Randomized, Double Blind Study With BF2.649 or Placebo	Completed	NCT01620554	Phase 2	BF2.649;Placebo
51	A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Narcolepsy	Completed	NCT02806908	Phase 2	JZP-110;Placebo
52	A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy	Completed	NCT01006122	Phase 2	Placebo;PF-03654746
53	A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Obstructive Sleep Apnea	Completed	NCT02806895	Phase 2	JZP-110;Placebo
54	Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness	Completed	NCT03624920	Phase 2	THN102 Dosage A;THN102 Dosage B;THN102 Dosage C
55	A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2	Completed	NCT02512588	Phase 2	BTD-001;Placebo
56	A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors	Completed	NCT01183312	Phase 1, Phase 2	Flumazenil
57	A Four-week, Double-blind, Placebo-controlled, Randomized, Cross-over Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness	Completed	NCT01485770	Phase 2	ADX-N05;Placebo
58	Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines	Recruiting	NCT03772314	Phase 2	Modafinil;Amphetamine-Dextroamphetamine
59	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension	Recruiting	NCT04886518	Phase 2	Pitolisant Oral Tablet;Placebo oral tablet
60	Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes	Recruiting	NCT04026958	Phase 2	Clarithromycin;Placebo
61	A Double-blind, Randomized, Placebo-controlled, Parallel, Study to Assess the Efficacy and Safety of XW10172 MR for the Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease	Not yet recruiting	NCT05056194	Phase 2	Valiloxybate
62	Phase IIa, Randomized, Double-blind, Placebo-controlled, 3-period Crossover, Adaptive Dose Design, Clinical Trial to Evaluate Safety & Efficacy of MK0249 in Treating Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome Appropriately Using nCPAP Therapy.	Terminated	NCT00620659	Phase 2	Comparator: MK0249;Comparator: placebo;Comparator: modafinil
63	A Randomized, Phase II Placebo-controlled Study of the Use of Extended-release Methylphenidate or Modafinil for the Treatment of Excessive Daytime Sleepiness in Children Following Cancer Therapy	Terminated	NCT01348607	Phase 2	methylphenidate hydrochloride;modafinil;placebo
64	A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia	Completed	NCT04091438	Phase 1	TAK-925;TAK-925 Placebo
65	A Phase 1b Randomized, Double-blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of TAK-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of CPAP	Completed	NCT04091425	Phase 1	TAK-925;Placebo
66	A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ABT-652 Administered Once Daily to Subjects With an Excessive Daytime Sleepiness Disorder	Completed	NCT01124851	Phase 1	ABT-652;Placebo
67	A Double-Blind, Phase 1, Single-Center, Single-Ascending Dose Study of JZP-386 Compared to Xyrem® vs. Placebo to Evaluate the Safety and Pharmacokinetics	Completed	NCT02215499	Phase 1	Placebo;Sodium Oxybate;JZP-386
68	Is the Daytime Sleepiness Based on Epworth Sleepiness Scale a Good Way to Assess Taiwanese With Suspected Obstructive Sleep Apnea.	Unknown status	NCT04631783
69	Prevalence and Characteristics of Sleep Disturbances Among Psychiatric Inpatients	Unknown status	NCT04201392
70	Effects of Telemedicine and Humidification for Continous Positive Airway Pressure (CPAP) in OSAS.	Unknown status	NCT04300166
71	Hypersomnia in Major Depressive Disorder	Unknown status	NCT04006834
72	Comparison Between the Situational and the Time-of-day Recording of Daytime Sleepiness in Patients With the Assessment of a Sleep-related Respiratory Disorder	Unknown status	NCT04448470
73	Behavior of Psychomotor Vigilance Task Performance in Subjects With Obstructive Sleep Apnea With and Without Complaints of Daytime Sleepiness	Unknown status	NCT01562262
74	A Randomized Controlled Trial of Effects From a Mandibular Advancement Device in Patients With Obstructive Sleep Apnea and Snoring	Completed	NCT00477009
75	Sleep-Disordered Breathing and CPAP After Adenotonsillectomy in Children	Completed	NCT01554527
76	Improving the Assessment of Hypersomnolence	Completed	NCT02884505
77	Evaluation of Excessive Diurnal Sleepiness by the Expression and Activity of Salivary Amylase in Children With Hypersomnia.	Completed	NCT01926405
78	Psychosocial Adjunctive Treatment for Hypersomnia (PATH): A Pilot Trial	Completed	NCT03904238
79	Symptomatic Endometriosis of the Posterior Cul-de-sac is Associated With Impaired Sleep Quality, Excessive Daytime Sleepiness and Insomnia: a Case-control Study.	Completed	NCT02027142
80	An Eight Week, Double-Blind, Placebo Controlled, Adjunctive Study of the Primary Effects of the Use of Flexible Doses of Modafinil 50mg to 200mg, on the Negative Symptoms, Cognition, and Excessive Daytime Sleepiness in Schizophrenic Patients	Completed	NCT00546403		Modafinil;Placebo
81	The CPAP Effect in Severe Obstructive- Sleep- Apnea Patients Without Daytime Sleepiness: A Control Randomized Trial	Completed	NCT00491088
82	Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study (SMART DOCS)	Completed	NCT02037438
83	Community-Level Daytime Sleepiness: Social-Environmental Determinants, Consequences, and Impact of Sleep Apnea	Completed	NCT04176042
84	Assessing the Effect of the MYODM Food Supplement on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1	Completed	NCT04634682
85	Population-bases Study to Asses Prevalence of Sleep Disorders and Their Association With Cardiovascular Risk Factors and Diseases	Completed	NCT01877616
86	Differential Diagnosis and Management of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea: A Modified Delphi Consensus Panel Report	Completed	NCT05055271
87	The Role of the Circadian System in Neurological Sleep-wake Disorders: Assessment of Circadian and Homeostatic Sleep-wake Regulation and Vigilance With a Poly-nap Protocol	Completed	NCT03356938
88	The Feasibility of a Tailored Music Intervention to Reduce Symptoms of Sleep Disruption in Older Adults With Dementia	Completed	NCT04157244
89	A Placebo Control, Double Blind, Cross Over Study of Modafinil in Patients With Narcolepsy	Completed	NCT00174174		Modafinil
90	Anesthetic Management of Patients With Chronic Sleep Disorders	Completed	NCT04827329
91	The Effect of Acupressure on the Sleep Quality and Daytime Sleepiness of Surgical Nurses During the COVID-19 Pandemic Process	Completed	NCT04800939
92	Effect of Strength Training on the Quality and Duration of Sleep and Daytime Sleepiness of Institutionalized Adolescents: A Randomized Study	Completed	NCT03110731
93	Training Protocol for Various Sleep Disorders in Patients With Neurological Disorders	Completed	NCT00001664
94	Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment.	Completed	NCT00916253		Modafinil;Placebo
95	Diagnostic Validity Study and Cost Analysis of Domiciliary Respiratory	Completed	NCT00614952
96	Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia in Reference Centers Rare Hypersomnia	Completed	NCT03459300
97	Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia	Completed	NCT02913651
98	The Effects of Mindfulness on Disrupted Sleep in Bipolar Disorder	Completed	NCT01764035
99	Neurophysiologic Correlates of Hypersomnia: a High Density EEG Investigation	Completed	NCT01719315
100	Cognitive Assessment in Excessive Daytime Sleepiness: Electrophysiological Study.	Completed	NCT03446066
101	Effects of Litebook EDGE™ Phototherapy on Academic Performance and Functional Brain Activity in Non-Depressed Adolescents	Completed	NCT05383690
102	Feasibility of Detecting Within Subject Differences in Sleepiness With NextSense Earbud Electroencephalography Devices	Recruiting	NCT05066009
103	Swiss Primary Hypersomnolence and Narcolepsy Cohort Study	Recruiting	NCT04330963
104	Analysis of New Salivary Biomarkers to Evaluate Excessive Diurnal Sleepiness in Children With Hypersomnia	Recruiting	NCT05183464
105	Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence	Recruiting	NCT03998020
106	Voice Biomarkers to Predict Excessive Daytime Sleepiness	Recruiting	NCT04942574
107	Study on Disease Course and Quality of Life in Patients With Sleep Disorders (Mainz Sleep Registry)	Recruiting	NCT05321355
108	The Effect of Lifestyle Modifications on Aspects Related to Fatigue, Quality of Life, Health, and Sleepiness in Professional Drivers	Recruiting	NCT05096130
109	Coordination of Rare Diseases at Sanford	Recruiting	NCT01793168
110	Integral Physiological Adaptations to Carbohydrate Periodization	Recruiting	NCT05464342
111	A Multi-Signal Based Monitoring System for CNS Hypersomnias : A 10-year Longitudinal Study	Recruiting	NCT05443373
112	Validating the Use of a Novel Subjectively Reported Sleep Vital Sign for the Identification and Management of Sleep Disorders	Active, not recruiting	NCT03018912
113	Idiopathic Hypersomnia - a Retrospective Characterization Study	Enrolling by invitation	NCT05150977
114	Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments	Enrolling by invitation	NCT05371483
115	Multiple Reaction Monitoring (MRM) Versus I 125 Radioimmunoassay (RIA) for the Quantification of Orexin-A/Hypocretin-1 Levels in Cerebrospinal Fluid: a Prospective Diagnostic Validation Study in Patients With Hypersomnolence	Not yet recruiting	NCT05615584
116	Feasibility Study of Utilizing At-Home Electroencephalography Monitoring for Diagnosing and Treatment Monitoring of Hypersomnia	Not yet recruiting	NCT05627388
117	Randomized Control Trial to Compare Patient Outcomes Following Unattended Polysomnography Versus In-lab Polysomnography for Sleep Apnea and Comorbid Sleep Disorders	Not yet recruiting	NCT05230394
118	An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy	No longer available	NCT03433131		Pitolisant
119	Disrupted Sleep in the Elderly: Light Exposure Studies	Suspended	NCT00427323
120	'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'	Suspended	NCT04419792
121	Use of CPAP to Reduce Arterial Stiffness in Moderate to Severe Obstructive Sleep Apnea, Without Excessive Daytime Sleepiness (STIFFSLEEP)	Terminated	NCT02273089
122	Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy	Terminated	NCT03198156
123	Melatonin for Circadian Sleep Disorders in the Blind	Terminated	NCT00911053		Melatonin
124	Effect of a Structured Physical Activity Program on Sleep Quality and Sleepiness in Parkinson's Disease	Terminated	NCT01544465
125	Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease	Withdrawn	NCT00393562		modafinil;methylphenidate
126	Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem®) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia	Withdrawn	NCT03626727	Early Phase 1	Sodium Oxybate Oral Solution [Xyrem]
127	STaRtS: Start Times and Restful Sleep	Withdrawn	NCT04049682

Search NIH Clinical Center for Recurrent Hypersomnia

Cochrane evidence based reviews: disorders of excessive somnolence

Sources

Genetic Tests for Recurrent Hypersomnia

Sources

Anatomical Context for Recurrent Hypersomnia

Organs/tissues related to Recurrent Hypersomnia:

MalaCards : Brain, Breast, Heart, Thalamus

Sources

Publications for Recurrent Hypersomnia

Articles related to Recurrent Hypersomnia:

(showing 51, show less)

#	Title	Authors	PMID	Year
1	A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions. ⁵³ ⁶²	Nozaki H...Nishizawa M	18226957	2009
2	Different circadian rest-active rhythms in Kleine-Levin syndrome: a prospective and case-control study. ⁶²	Lin C...Guilleminault C	33851710	2021
3	[Tularaemia in two patients referred on suspicion of cancer mammae and cancer occulta]. ⁶²	Nielsen CB...Simonsen H	33000721	2020
4	Usefulness of brain SPECT imaging in the study of recurrent hypersomnia: Kleine-Levin syndrome. ⁶²	Ramirez Ocana D...Puentes Zarzuela C	28869046	2019
5	Kleine-Levin syndrome: A neuropsychiatric disorder. ⁶²	Arnulf I...Dodet P	29606318	2018
6	Recurrent Hypersomnia and Autonomic Dysregulation in Posttraumatic Stress Disorder. ⁶²	Gupta MA	29117891	2017
7	A Case of Recurrent Hypersomnia With Autonomic Dysfunction. ⁶²	Mahmoudi M...Kothare SV	28633719	2017
8	Migraine with brainstem aura presenting as recurrent hypersomnia (Kleine-Levin syndrome). ⁶²	Nesbitt AD...Leschziner GD	27343267	2016
9	Kleine-Levin Syndrome. ⁶²	Miglis MG...Guilleminault C	27137943	2016
10	Recurrent hypersomnia in an 18-year old boy: CSF hypocretin level and MSLT findings. ⁶²	Cho JW...Kim JH	26323648	2016
11	Do the Symptoms of Kleine-Levin Syndrome Correlate With the Hypometabolism of the Thalamus on FDG PET? ⁶²	Xie H...Song W	26562572	2016
12	Menstruation-Related Hypersomnia Treated with Hormonal Contraception: Case Report and Review of Literature. ⁶²	Suau GM...Romaguera J	26932284	2016
13	Circadian disruption: New clinical perspective of disease pathology and basis for chronotherapeutic intervention. ⁶²	Smolensky MH...Portaluppi F	27308960	2016
14	Recurrent hypersomnia: Report of medication-responsive cases. ⁶²	Perin BV...Forcelini CM	26483951	2015
15	Narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time: a cluster analysis. ⁶²	Sonka K...Billiard M	25576137	2015
16	Misdiagnosis of menstruation-related recurrent hypersomnia as epilepsy in a patient with generalized epileptic discharges. ⁶²	Benbir G...Yeni N	25878739	2015
17	Treatment of Kleine-Levin syndrome with acetazolamide. ⁶²	Kapson B...Spiegel R	25317098	2014
18	Kleine-Levin syndrome: a case report and review of literature. ⁶²	Das S...Raghuvanshi S	24630285	2014
19	Kleine-Levin syndrome: a review. ⁶²	Miglis MG...Guilleminault C	24470783	2014
20	[The Kleine-Levin syndrome: new aspects of a rare disease]. ⁶²	Mayer G	23942582	2013
21	Recurrent hypersomnia following traumatic brain injury. ⁶²	Billiard M...Podesta C	23499199	2013
22	Diagnosis and management of central hypersomnias. ⁶²	Sonka K...Susta M	22973425	2012
23	Recurrent hypersomnia due to occult hepatic encephalopathy. ⁶²	Boulos MI...Murray BJ	22154356	2012
24	A rapid screening test for depression in junior high school children. ⁶²	Chung MS...Chou P	21872817	2011
25	Recurrent hypersomnia: a review of 339 cases. ⁶²	Billiard M...Besset A	20970360	2011
26	Familial recurrent hypersomnia: two siblings with Kleine-Levin syndrome and menstrual-related hypersomnia. ⁶²	Rocamora R...Vela-Bueno A	20404354	2010
27	[A case of recurrent hypersomnia with excellent response to lithium carbonate]. ⁶²	Ogawa T...Kato H	21061548	2010
28	Non-convulsive status epilepticus presenting as recurrent hypersomnia. ⁶²	Sharma A...Modi M	20463123	2010
29	Gabapentin for Kleine-Levin syndrome. ⁶²	Itokawa K...Araki N	19571456	2009
30	Polysomnography in Kleine-Levin syndrome. ⁶²	Huang YS...Guilleminault C	18316691	2008
31	Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. ⁶²	Morgenthaler TI...Standards of Practice Committee of the American Academy of Sleep Medicine	18246980	2007
32	Hypersomnias of central origin. ⁶²	Young TJ...Silber MH	16963696	2006
33	Differential diagnosis in hypersomnia. ⁶²	Dauvilliers Y	16522270	2006
34	Hypersomnia. ⁶²	Dauvilliers Y...Buguet A	16416710	2005
35	Case study: differences in human Per2 gene expression, body temperature, cortisol, and melatonin parameters in remission and hypersomnia in a patient with recurrent hypersomnia. ⁶²	Tomoda A...Miike T	14535361	2003
36	[Recurrent hypersomnia]. ⁶²	Ogawa Y...Shimizu T	14503208	2003
37	Decreased blood flow of the left thalamus during somnolent episodes in a case of recurrent hypersomnia. ⁶²	Nose I...Kuwahara H	12047594	2002
38	Recurrent hyper- and hyposomnia: a new diagnostic entity? Polysomnographic findings and a 30-year follow-up. ⁶²	Hauri PJ	14592248	2002
39	[Disorders of awakening. Second part: secondary disorders]. ⁶²	Billiard M...Ondze B	11438768	2001
40	Kleine Levin syndrome (KLS) in young females. ⁶²	Kesler A...Lavie P	10875563	2000
41	Prolonged polysomnography in a case with recurrent hypersomnia. ⁶²	Tanabe E...Kojima T	9628153	1998
42	[Recurrent hypersomnia]. ⁶²	Suzuki H	9503836	1998
43	Recurrent hypersomina: a case report with polysomnographic findings. ⁶²	Chung KF	11847365	1997
44	Treatment of recurrent hypersomnia with methylcobalamin (vitamin B12): a case report. ⁶²	Yamada N	8726119	1995
45	Electrophysiological and immunogenetic findings in recurrent monosymptomatic-type hypersomnia: a study of two unrelated Italian cases. ⁶²	Manni R...Tartara A	8256576	1993
46	Recurrent hypersomnia in two adolescent males with Asperger's syndrome. ⁶²	Berthier ML...Tolosa ES	1644738	1992
47	[Recurrent hypersomnia caused by acute toluene poisoning]. ⁶²	Sureda B...Quesada J	2361041	1990
48	[Recurrent hypersomnia]. ⁶²	Billiard M...Cadilhac J	3047832	1988
49	Recurrent hypersomnia secondary to sleep apnea. ⁶²	Kuban K	718480	1978
50	Recurrent hypersomnia secondary to sleep apnea. ⁶²	Spira HM...Scheinberg P	889488	1977
51	[Kleine-Levin syndrome (recurrent hypersomnia of male adolescents]. ⁶²	Fresco R...Mouren P	5559004	1971

Sources

Genes for Recurrent Hypersomnia

Genes related to Recurrent Hypersomnia (0 elite genes):

(showing 11, show less)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HCRT	Hypocretin Neuropeptide Precursor	Protein Coding	17.64	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18226957
2	HLA-DQB1	Major Histocompatibility Complex, Class II, DQ Beta 1	Protein Coding	7.01	DISEASES inferred ¹⁴
3	LMOD3	Leiomodin 3	Protein Coding	6.96	DISEASES inferred ¹⁴
4	TRANK1	Tetratricopeptide Repeat And Ankyrin Repeat Containing 1	Protein Coding	6.66	DISEASES inferred ¹⁴
5	TOR1B	Torsin Family 1 Member B	Protein Coding	5.96	DISEASES inferred ¹⁴
6	PNMA2	PNMA Family Member 2	Protein Coding	5.39	DISEASES inferred ¹⁴
7	IGLON5	IgLON Family Member 5	Protein Coding	5.25	DISEASES inferred ¹⁴
8	HCRTR2	Hypocretin Receptor 2	Protein Coding	5.25	DISEASES inferred ¹⁴
9	P2RY11	Purinergic Receptor P2Y11	Protein Coding	5.07	DISEASES inferred ¹⁴
10	HRH3	Histamine Receptor H3	Protein Coding	5.07	DISEASES inferred ¹⁴
11	LGI1	Leucine Rich Glioma Inactivated 1	Protein Coding	5.06	DISEASES inferred ¹⁴